Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1-Reference-Cited by-同舟云学术

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1

Published:2018-09-05 Issue:1 Volume:78 Page:150-152
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Mammen Andrew L,Rajan Arun,Pak Katherine,Lehky Tanya,Casciola-Rosen Livia,Donahue Renee N,Lepone Lauren M,Zekeridou Anastasia,Pittock Sean J,Hassan Raffit,Schlom Jeffrey,Gulley James L

Funder

National Institute of Arthritis and Musculoskeletal and Skin Diseases

National Cancer Institute

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference6 articles.

1. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials;Kelly;Cancer,2018

2. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial;Heery;Lancet Oncol,2017

3. Thymoma associated with autoimmune diseases: 85 cases and literature review

4. Chen JH , Lee KY , Hu CJ , et al . Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review. Medicine 2017;96:e9262.doi:10.1097/MD.0000000000009262

5. B-cell lymphopenia and hypogammaglobulinemia in thymoma patients

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer;Cell & Bioscience;2024-09-12

2. Toxicity in the era of immune checkpoint inhibitor therapy;Frontiers in Immunology;2024-08-23

3. Peripheral nervous system immune-related adverse events due to checkpoint inhibition;Nature Reviews Neurology;2024-08-09

4. Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach;Expert Opinion on Drug Safety;2024-06-03

5. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors;Japanese Journal of Clinical Oncology;2024-05-20